Zevra Therapeutics, Inc. (ZVRA)
Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Nicole Oschner - Vice President of Investor Relations and Corporate Communications Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer and Executive Vice President of Business Development Conference Call Participants Louise Chen - Cantor Fitzgerald Tim Lugo - William Blair Oren Livnat - H.C. Wainwright Operator Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.15 per share a year ago.
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
